Rakuten Medical’s Post

Lung-MAP is a first-of-its-kind clinical trial model that uses a multi-drug, targeted screening approach to match patients with sub-studies testing investigational new treatments based on their unique tumor profiles. https://ow.ly/klob50Q1fG1 #FriendsDosing #DoseOptimization

#cartcelltherapy Dual acting CAR T-cell therapy The more the epitopes the stronger and better the effect. Be it for COVID vaccines or for polyclonal antibodies or for CAR T Cell therapies the universal rule do not let the target go which is only possible by effective binding.

We recall the frequent occurrence of ILD in the clinical data for MORAb-202 presented at ASCO22. At the same conference, Eisai Co., Ltd. presented research indicating that body-surface-area-based dosing could reduce the risk of ILD compared to body-weight-based dosing. Ref: https://lnkd.in/gP2Ebjx7. https://lnkd.in/gBfDFU7D At #AACR24, Eisai presented intriguing new findings: 📌In vitro analysis showed that the concentration of eribulin was significantly higher in cells with high TROP2 expression. 📌In vivo analysis revealed that the concentration of eribulin in tumor tissue was approximately 10 times higher in the model with high TROP2 expression. 📌In lung tissue, eribulin distribution was dose-dependent regardless of TROP2 expression. Immunofluorescence assay confirmed that TROP2-eribulin was localized to alveolar macrophages. In experiments using an Fc receptor inhibitor, the concentration of eribulin released from macrophages was significantly reduced. Ref: https://lnkd.in/g5Qdp_zX

The findings in the peer-reviewed research published by JAMA Oncology signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions about the risk of clinically significant #prostatecancer. As Lynx Dx Chief Medical and Commercial Officer, Spencer Heaton, notes: “The research findings demonstrate the potential of MPS2 to facilitate more informed decision-making about a patient’s best course of treatment by shedding new light on a serious condition that is notoriously difficult to diagnose.” Read the full announcement: https://lnkd.in/gwKU_Tun #ProstateCancer #Innovation #CancerResearch

RINGSIDE phase 2 data in desmoid tumors show that AL102 1.2 mg once daily achieved ORR of 83% and reduction in tumor volume and in T2W signal intensity in 88% and 85% of the evaluable population, respectively. The Ayala team is very grateful to the patients, their families and the investigators participating in the study. #desmoid #GSI #AL102 #RINGSIDE

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

Cellectar recently announced topline data for Iopofosine, their potential first-in-class, targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia (WM). Results were promising with its primary endpoint met with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value < 0.0001]). The overall response rate (ORR) in evaluable patients was 75.6%, and 100% of patients experienced disease control. https://lnkd.in/eiPgcXqn #oncology #clinicaltrials #biotech #radiotherapy

A new breakthrough platform will enable non-invasive clinical assays in time for clinical decision. The “Rapid, Reproducible, Rare Cell 3D Expansion” (R3CE) is able to generate solid tumors, rare cells, Circulating-Tumor-Cells (CTCs) and more. This opportunity will allow physicians to accurately predict drug resistance acquired over treatment cycles. It was developed by Dr. Mark D Pegram, Dr. Ying C Chang, Dr. Wen-Hung Kuo, Dr. Yu Zong, Dr. Yen-Jang Huang, and Dr. Jia-Yang Chen. Read more about the R3CE’s capabilities here ⬇️ https://lnkd.in/gsyY4YMY

Bruce Levine and Carl June weigh in on the FDA investigation into secondary T-cell cancers post CAR-T treatment. Despite the FDA probe, the experts affirm that the benefits of CAR-T therapies far outweigh potential risks in the majority of cases. The Nature Medicine Comment emphasizes the importance of continuing to offer commercial CAR-T products based on up-to-date safety information. Read the full article here: https://lnkd.in/g7cxEkAa Link to Nature Medicine Comment: https://lnkd.in/giRZ7_xz #OCBio, #OrangeCountyBio, #CGT, #CellandGeneTh

NSCLC Mechanisms of resistance to targeted therapy “EGFR C797X (C797S or C797G) can develop different allelic contexts with T790M. Currently defined allelic contexts of EGFR C797X relative to T790M include configurations either in cis (on the same allele) or in trans (on different alleles). The specific allelic context of EGFR C797X has been associated with the effectiveness of subsequent treatments. However, most of the supporting evidence comes from preclinical studies and isolated case reports.7, 8, 9, 10, 11 Moreover, evidence is scant regarding the frequency and clinical outcomes of patients harboring different allelic contexts of C797X. In this multicenter collaboration, we characterized the heterogeneity among EGFR C797X–mutant advanced NSCLC on the basis of the allelic context of C797X. In addition to clinicopathologic features, the subtypes exhibited marked differences in mutational landscape, responses to the first subsequent therapy, and clinical outcomes.” #NSCLC #resistance #EGFR #targetedtherapy #alleliccontext #cis #trans